Patent ID: 11931414
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 12:
13. The Ligand-Drug Conjugate compound of claim 10 wherein the Peptide Cleavable Unit comprises a peptide sequence containing a dipeptide having the structure of:, wherein R34 is benzyl, methyl, isopropyl, isobutyl, sec-butyl, or —CH(OH)CH3, or R34 has the structure of, , wherein the asterisk indicates the site of covalent attachment to the dipeptide backbone; and
R35 is methyl, —(CH2)4—NH2, —(CH2)3NH(C═O)NH2, —(CH2)3NH(C═NH)NH2, or —(CH2)2CO2H; and
wherein the wavy line adjacent to the carbonyl carbon atom indicates the site of covalent attachment to Y and the wavy line adjacent to the nitrogen atom indicates the site of covalent attachment of the dipeptide to the remainder of the peptide sequence,
wherein said covalent attachments are through amide bonds and wherein the dipeptide provides a recognition site for protease cleavage of the amide bond to Y to initiate release of D+ as a NAMPTi compound, or
wherein the Peptide Cleavable Unit is a dipeptide selected from the group consisting of -Phe-Lys-, -Val-Ala-, -Val-Lys-, -Ala-Lys-, -Val-Cit-, -Phe-Cit-, -Leu-Cit-, -Ile-Cit-, -Phe-Arg-, and -Trp-Cit-, wherein Cit is citrulline.